Improving Accessibility to Patients with Interstitial Lung Disease (ILD): Barriers to Early Diagnosis and Timely Treatment in Latin America
Delayed initiation of effective antifibrotic therapy in patients with interstitial lung diseases (ILD) may influence the progression and outcome of the disease. This study analyzes the differences in the journey of patients with ILD in the Brazilian and Mexican health systems. An evaluative study wa...
Gespeichert in:
| Veröffentlicht in: | International journal of environmental research and public health 2024-05, Vol.21 (5), p.647 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 5 |
| container_start_page | 647 |
| container_title | International journal of environmental research and public health |
| container_volume | 21 |
| creator | Figueiredo, Ricardo G Duarte, Nathalia Filgueiras Vilaça Campos, Daniela Carla Barbosa de Jesus Diaz Verduzco, Manuel Márquez, Ángel Alemán de Araujo, Gabriela Tannus Branco Rubin, Adalberto Sperb |
| description | Delayed initiation of effective antifibrotic therapy in patients with interstitial lung diseases (ILD) may influence the progression and outcome of the disease. This study analyzes the differences in the journey of patients with ILD in the Brazilian and Mexican health systems. An evaluative study was conducted in reference centers for interstitial lung diseases in Brazil and Mexico with a panel of four specialists. The patient's journey in both countries begins when the patient seeks medical care after observing a chronic respiratory symptom. In both countries, due to diagnostic complexity, these patients arrive at ILD referral centers at an advanced stage of the disease. Once diagnosis is established, the treatment onset differs between Mexico and Brazil. In Brazil, access to antifibrotic drugs through the public health system has been a significant challenge, and their cost makes them unaffordable for most people. This situation forces medical specialists to provide only supportive care to patients until these drugs can be accessed. In Mexico, antifibrotics have been available in health sectors since 2018. Brazil and Mexico have several similarities regarding the initial journey of the patient due to diagnosis difficulties. Still, the outcome tends to be different due to a difference in access to treatment with antifibrotics. For this reason, advancing health policies that ensure proper treatment for patients with ILD is crucial for the sustainability and reliability of the health system. |
| doi_str_mv | 10.3390/ijerph21050647 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3060383719</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3060383719</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1637-d89408d3b24a917e46b21b58ceec55761450888f0e4595f9cf3736023e2e04ce3</originalsourceid><addsrcrecordid>eNpdkUlv2zAQhYmiRbO01x4LAr04ByekuIjqzdkNCEgP7lmg6FEyhkS5JJXAvyF_OgySFklPHBDfe7M8Qr5xdixExU5wA2F7V3CmmJblB7LPtWZzqRn_-KbeIwcxbhgTRurqM9kTpqy40XyfPC6HbRjv0d_ShXMQI7bYY9rRNNJfNiH4FOkDpju69AlCTJjQ9rSesuAcI9gIdLasz49-0lMbAmbkWXphQ7_LgL31Y8RIrV_TFQ6QP1cBbBqyL0VP69zC08UAAZ39Qj51to_w9fU9JL8vL1Zn1_P65mp5tqjnjmtRztemksysRVtIW_ESpG4L3irjAJxSpeZSMWNMx0CqSnWV60QpNCsEFMCkA3FIZi--efM_E8TUDBgd9L31ME6xEUznS4mSVxn98R-6Gafg83SZyu5cKcMzdfxCuTDGGKBrtgEHG3YNZ81zTM37mLLg-6vt1A6w_of_zUU8Aa89jjU</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3059515581</pqid></control><display><type>article</type><title>Improving Accessibility to Patients with Interstitial Lung Disease (ILD): Barriers to Early Diagnosis and Timely Treatment in Latin America</title><source>MDPI - Multidisciplinary Digital Publishing Institute</source><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>Free Full-Text Journals in Chemistry</source><source>PubMed Central Open Access</source><creator>Figueiredo, Ricardo G ; Duarte, Nathalia Filgueiras Vilaça ; Campos, Daniela Carla Barbosa ; de Jesus Diaz Verduzco, Manuel ; Márquez, Ángel Alemán ; de Araujo, Gabriela Tannus Branco ; Rubin, Adalberto Sperb</creator><creatorcontrib>Figueiredo, Ricardo G ; Duarte, Nathalia Filgueiras Vilaça ; Campos, Daniela Carla Barbosa ; de Jesus Diaz Verduzco, Manuel ; Márquez, Ángel Alemán ; de Araujo, Gabriela Tannus Branco ; Rubin, Adalberto Sperb</creatorcontrib><description>Delayed initiation of effective antifibrotic therapy in patients with interstitial lung diseases (ILD) may influence the progression and outcome of the disease. This study analyzes the differences in the journey of patients with ILD in the Brazilian and Mexican health systems. An evaluative study was conducted in reference centers for interstitial lung diseases in Brazil and Mexico with a panel of four specialists. The patient's journey in both countries begins when the patient seeks medical care after observing a chronic respiratory symptom. In both countries, due to diagnostic complexity, these patients arrive at ILD referral centers at an advanced stage of the disease. Once diagnosis is established, the treatment onset differs between Mexico and Brazil. In Brazil, access to antifibrotic drugs through the public health system has been a significant challenge, and their cost makes them unaffordable for most people. This situation forces medical specialists to provide only supportive care to patients until these drugs can be accessed. In Mexico, antifibrotics have been available in health sectors since 2018. Brazil and Mexico have several similarities regarding the initial journey of the patient due to diagnosis difficulties. Still, the outcome tends to be different due to a difference in access to treatment with antifibrotics. For this reason, advancing health policies that ensure proper treatment for patients with ILD is crucial for the sustainability and reliability of the health system.</description><identifier>ISSN: 1660-4601</identifier><identifier>ISSN: 1661-7827</identifier><identifier>EISSN: 1660-4601</identifier><identifier>DOI: 10.3390/ijerph21050647</identifier><identifier>PMID: 38791861</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>Blood & organ donations ; Brazil ; Early Diagnosis ; Employees ; Health care policy ; Health insurance ; Health Services Accessibility ; Humans ; Insurance coverage ; Lung diseases ; Lung Diseases, Interstitial - diagnosis ; Lung Diseases, Interstitial - drug therapy ; Lung Diseases, Interstitial - therapy ; Medical prognosis ; Mexico ; Patients ; Pneumonia ; Population ; Private sector ; Public health ; Pulmonary fibrosis ; Socioeconomic factors ; Trends</subject><ispartof>International journal of environmental research and public health, 2024-05, Vol.21 (5), p.647</ispartof><rights>2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c1637-d89408d3b24a917e46b21b58ceec55761450888f0e4595f9cf3736023e2e04ce3</cites><orcidid>0000-0002-8033-3168 ; 0000-0003-2128-2775</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38791861$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Figueiredo, Ricardo G</creatorcontrib><creatorcontrib>Duarte, Nathalia Filgueiras Vilaça</creatorcontrib><creatorcontrib>Campos, Daniela Carla Barbosa</creatorcontrib><creatorcontrib>de Jesus Diaz Verduzco, Manuel</creatorcontrib><creatorcontrib>Márquez, Ángel Alemán</creatorcontrib><creatorcontrib>de Araujo, Gabriela Tannus Branco</creatorcontrib><creatorcontrib>Rubin, Adalberto Sperb</creatorcontrib><title>Improving Accessibility to Patients with Interstitial Lung Disease (ILD): Barriers to Early Diagnosis and Timely Treatment in Latin America</title><title>International journal of environmental research and public health</title><addtitle>Int J Environ Res Public Health</addtitle><description>Delayed initiation of effective antifibrotic therapy in patients with interstitial lung diseases (ILD) may influence the progression and outcome of the disease. This study analyzes the differences in the journey of patients with ILD in the Brazilian and Mexican health systems. An evaluative study was conducted in reference centers for interstitial lung diseases in Brazil and Mexico with a panel of four specialists. The patient's journey in both countries begins when the patient seeks medical care after observing a chronic respiratory symptom. In both countries, due to diagnostic complexity, these patients arrive at ILD referral centers at an advanced stage of the disease. Once diagnosis is established, the treatment onset differs between Mexico and Brazil. In Brazil, access to antifibrotic drugs through the public health system has been a significant challenge, and their cost makes them unaffordable for most people. This situation forces medical specialists to provide only supportive care to patients until these drugs can be accessed. In Mexico, antifibrotics have been available in health sectors since 2018. Brazil and Mexico have several similarities regarding the initial journey of the patient due to diagnosis difficulties. Still, the outcome tends to be different due to a difference in access to treatment with antifibrotics. For this reason, advancing health policies that ensure proper treatment for patients with ILD is crucial for the sustainability and reliability of the health system.</description><subject>Blood & organ donations</subject><subject>Brazil</subject><subject>Early Diagnosis</subject><subject>Employees</subject><subject>Health care policy</subject><subject>Health insurance</subject><subject>Health Services Accessibility</subject><subject>Humans</subject><subject>Insurance coverage</subject><subject>Lung diseases</subject><subject>Lung Diseases, Interstitial - diagnosis</subject><subject>Lung Diseases, Interstitial - drug therapy</subject><subject>Lung Diseases, Interstitial - therapy</subject><subject>Medical prognosis</subject><subject>Mexico</subject><subject>Patients</subject><subject>Pneumonia</subject><subject>Population</subject><subject>Private sector</subject><subject>Public health</subject><subject>Pulmonary fibrosis</subject><subject>Socioeconomic factors</subject><subject>Trends</subject><issn>1660-4601</issn><issn>1661-7827</issn><issn>1660-4601</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNpdkUlv2zAQhYmiRbO01x4LAr04ByekuIjqzdkNCEgP7lmg6FEyhkS5JJXAvyF_OgySFklPHBDfe7M8Qr5xdixExU5wA2F7V3CmmJblB7LPtWZzqRn_-KbeIwcxbhgTRurqM9kTpqy40XyfPC6HbRjv0d_ShXMQI7bYY9rRNNJfNiH4FOkDpju69AlCTJjQ9rSesuAcI9gIdLasz49-0lMbAmbkWXphQ7_LgL31Y8RIrV_TFQ6QP1cBbBqyL0VP69zC08UAAZ39Qj51to_w9fU9JL8vL1Zn1_P65mp5tqjnjmtRztemksysRVtIW_ESpG4L3irjAJxSpeZSMWNMx0CqSnWV60QpNCsEFMCkA3FIZi--efM_E8TUDBgd9L31ME6xEUznS4mSVxn98R-6Gafg83SZyu5cKcMzdfxCuTDGGKBrtgEHG3YNZ81zTM37mLLg-6vt1A6w_of_zUU8Aa89jjU</recordid><startdate>20240519</startdate><enddate>20240519</enddate><creator>Figueiredo, Ricardo G</creator><creator>Duarte, Nathalia Filgueiras Vilaça</creator><creator>Campos, Daniela Carla Barbosa</creator><creator>de Jesus Diaz Verduzco, Manuel</creator><creator>Márquez, Ángel Alemán</creator><creator>de Araujo, Gabriela Tannus Branco</creator><creator>Rubin, Adalberto Sperb</creator><general>MDPI AG</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>COVID</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-8033-3168</orcidid><orcidid>https://orcid.org/0000-0003-2128-2775</orcidid></search><sort><creationdate>20240519</creationdate><title>Improving Accessibility to Patients with Interstitial Lung Disease (ILD): Barriers to Early Diagnosis and Timely Treatment in Latin America</title><author>Figueiredo, Ricardo G ; Duarte, Nathalia Filgueiras Vilaça ; Campos, Daniela Carla Barbosa ; de Jesus Diaz Verduzco, Manuel ; Márquez, Ángel Alemán ; de Araujo, Gabriela Tannus Branco ; Rubin, Adalberto Sperb</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1637-d89408d3b24a917e46b21b58ceec55761450888f0e4595f9cf3736023e2e04ce3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Blood & organ donations</topic><topic>Brazil</topic><topic>Early Diagnosis</topic><topic>Employees</topic><topic>Health care policy</topic><topic>Health insurance</topic><topic>Health Services Accessibility</topic><topic>Humans</topic><topic>Insurance coverage</topic><topic>Lung diseases</topic><topic>Lung Diseases, Interstitial - diagnosis</topic><topic>Lung Diseases, Interstitial - drug therapy</topic><topic>Lung Diseases, Interstitial - therapy</topic><topic>Medical prognosis</topic><topic>Mexico</topic><topic>Patients</topic><topic>Pneumonia</topic><topic>Population</topic><topic>Private sector</topic><topic>Public health</topic><topic>Pulmonary fibrosis</topic><topic>Socioeconomic factors</topic><topic>Trends</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Figueiredo, Ricardo G</creatorcontrib><creatorcontrib>Duarte, Nathalia Filgueiras Vilaça</creatorcontrib><creatorcontrib>Campos, Daniela Carla Barbosa</creatorcontrib><creatorcontrib>de Jesus Diaz Verduzco, Manuel</creatorcontrib><creatorcontrib>Márquez, Ángel Alemán</creatorcontrib><creatorcontrib>de Araujo, Gabriela Tannus Branco</creatorcontrib><creatorcontrib>Rubin, Adalberto Sperb</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Coronavirus Research Database</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>International journal of environmental research and public health</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Figueiredo, Ricardo G</au><au>Duarte, Nathalia Filgueiras Vilaça</au><au>Campos, Daniela Carla Barbosa</au><au>de Jesus Diaz Verduzco, Manuel</au><au>Márquez, Ángel Alemán</au><au>de Araujo, Gabriela Tannus Branco</au><au>Rubin, Adalberto Sperb</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Improving Accessibility to Patients with Interstitial Lung Disease (ILD): Barriers to Early Diagnosis and Timely Treatment in Latin America</atitle><jtitle>International journal of environmental research and public health</jtitle><addtitle>Int J Environ Res Public Health</addtitle><date>2024-05-19</date><risdate>2024</risdate><volume>21</volume><issue>5</issue><spage>647</spage><pages>647-</pages><issn>1660-4601</issn><issn>1661-7827</issn><eissn>1660-4601</eissn><abstract>Delayed initiation of effective antifibrotic therapy in patients with interstitial lung diseases (ILD) may influence the progression and outcome of the disease. This study analyzes the differences in the journey of patients with ILD in the Brazilian and Mexican health systems. An evaluative study was conducted in reference centers for interstitial lung diseases in Brazil and Mexico with a panel of four specialists. The patient's journey in both countries begins when the patient seeks medical care after observing a chronic respiratory symptom. In both countries, due to diagnostic complexity, these patients arrive at ILD referral centers at an advanced stage of the disease. Once diagnosis is established, the treatment onset differs between Mexico and Brazil. In Brazil, access to antifibrotic drugs through the public health system has been a significant challenge, and their cost makes them unaffordable for most people. This situation forces medical specialists to provide only supportive care to patients until these drugs can be accessed. In Mexico, antifibrotics have been available in health sectors since 2018. Brazil and Mexico have several similarities regarding the initial journey of the patient due to diagnosis difficulties. Still, the outcome tends to be different due to a difference in access to treatment with antifibrotics. For this reason, advancing health policies that ensure proper treatment for patients with ILD is crucial for the sustainability and reliability of the health system.</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>38791861</pmid><doi>10.3390/ijerph21050647</doi><orcidid>https://orcid.org/0000-0002-8033-3168</orcidid><orcidid>https://orcid.org/0000-0003-2128-2775</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1660-4601 |
| ispartof | International journal of environmental research and public health, 2024-05, Vol.21 (5), p.647 |
| issn | 1660-4601 1661-7827 1660-4601 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_3060383719 |
| source | MDPI - Multidisciplinary Digital Publishing Institute; MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; Free Full-Text Journals in Chemistry; PubMed Central Open Access |
| subjects | Blood & organ donations Brazil Early Diagnosis Employees Health care policy Health insurance Health Services Accessibility Humans Insurance coverage Lung diseases Lung Diseases, Interstitial - diagnosis Lung Diseases, Interstitial - drug therapy Lung Diseases, Interstitial - therapy Medical prognosis Mexico Patients Pneumonia Population Private sector Public health Pulmonary fibrosis Socioeconomic factors Trends |
| title | Improving Accessibility to Patients with Interstitial Lung Disease (ILD): Barriers to Early Diagnosis and Timely Treatment in Latin America |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-14T02%3A49%3A07IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Improving%20Accessibility%20to%20Patients%20with%20Interstitial%20Lung%20Disease%20(ILD):%20Barriers%20to%20Early%20Diagnosis%20and%20Timely%20Treatment%20in%20Latin%20America&rft.jtitle=International%20journal%20of%20environmental%20research%20and%20public%20health&rft.au=Figueiredo,%20Ricardo%20G&rft.date=2024-05-19&rft.volume=21&rft.issue=5&rft.spage=647&rft.pages=647-&rft.issn=1660-4601&rft.eissn=1660-4601&rft_id=info:doi/10.3390/ijerph21050647&rft_dat=%3Cproquest_cross%3E3060383719%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3059515581&rft_id=info:pmid/38791861&rfr_iscdi=true |